Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-04-30T11:58:17.061Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of fluphenazine on basal prolactin concentrations

Published online by Cambridge University Press:  09 July 2009

R. J. Chalmers  and
E. H. Bennie
R. J. Chalmers*
Affiliation:
University Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, and Leverndale Hospital, Glasgow
E. H. Bennie
Affiliation:
University Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, and Leverndale Hospital, Glasgow
*
1Address for correspondence: Dr R. J. Chalmers, The Queen's College, 1 Park Drive, Glasgow G3 6LP.
Get access Rights & Permissions [Opens in a new window]

Synopsis

The effect of fluphenazine on basal human prolactin (hPRL) concentrations was studied in 10 male schizophrenics who had received fluphenazine treatment for at least 6 months, in 10 male alcoholics before and during the first week of fluphenazine treatment and in 8 alcoholics at daily intervals before and after treatment. The results were compared with basal hPRL concentrations in 17 healthy male controls. Investigations involved giving fluphenazine (Modecate) by intramuscular injection and taking blood samples at appropriate intervals by venepuncture. Basal hPRL concentrations were significantly increased in the schizophrenics. The alcoholics showed a significant rise in hPRL concentrations after fluphenazine but there was considerable variation in hPRL levels between individual patients. Most patients showed marked elevation of daily hPRL levels with peak concentrations occurring 5–6 days after the injection. The results demonstrate that fluphenazine elevates basal hPRL levels and the variation between levels of individual patients merits further investigation.

Type
Research Article
Information
Psychological Medicine , Volume 8 , Issue 3 , August 1978 , pp. 483 - 486
Copyright
Copyright © Cambridge University Press 1978

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Apostolakis, M., Kapetanakis, S., Lazos, G. & Madena-Pyrgaki, A. (1972). Plasma prolactin activity in patients with galactorrhoea after treatment with psychotropic drugs. In Lactogenic Hormones (ed. Wolstenholme, G. E. W. and Knight, J.), pp. 349–354. Churchill Livingstone: Edinburgh and London.Google Scholar
Bennie, E. M. & Kinnell, H. G. (1975). Dangerous offenders. Lancet ii, 1303.CrossRefGoogle Scholar
Beaumont, P. J. V., Gelder, M. G. & Friesen, H. G. (1974). The effects of phenothiazines on endocrine function. I. Patients with inappropriate lactation and amenorrhoea. British Journal of Psychiatry 124, 413–419.CrossRefGoogle Scholar
Curry, S. H. (1971). Chlorpromazine: concentrations in plasma, excretion in urine and duration of effect. Proceedings of the Royal Society of Medicine 64, 285–289.CrossRefGoogle ScholarPubMed
Frantz, A. G., Kleinberg, D. L. & Noel, G. L. (1972). Physiological and pathological secretion of human prolactin studied by in vitro bio-assay. In Lactogenic Hormones (ed. Wolstenholme, G. E. W. and Knight, J.), pp. 137–150. Churchill Livingstone: Edinburgh and London.Google Scholar
Friesen, H. G., Guyda, E., Hwang, P., Tyson, J. E. & Barbeau, A. (1972). Functional evaluation of prolactin secretion: a guide to therapy. Journal of Clinical Investigation 51, 706–709.CrossRefGoogle ScholarPubMed
Gade, E. B. & Heinrich, K. (1955). Klinische Beobachtungen bei Magaphenbehandlung in der Psychiatrie. Nervenarzt 26, 49–54.Google Scholar
Kamberi, I. A., Mical, R. S. & Porter, J. D. (1971). Effect of anterior pituitary perfusion and intraventricular injection of catecholamines on prolactin release. Endocrinology 88, 1012–1021.CrossRefGoogle ScholarPubMed
Kolakowska, T., Wiles, D. H., McNeilly, A. S. & Gelder, M. G. (1975). Correlation between plasma levels of prolactin and chlorpromazine. Psychological Medicine 5, 214–216.CrossRefGoogle ScholarPubMed
Meltzer, H. Y., Victor, M. D. & Fang, S. (1976). The effect of neuroleptics on serum prolactin in schizophrenic patients. Archives of General Psychiatry 33, 279–286.CrossRefGoogle ScholarPubMed
Polishuk, W. Z. & Kulcsar, S. (1956). Effects of chlorpromazine on pituitary function. Journal of Clinical Endocrinology 16, 292–293.CrossRefGoogle ScholarPubMed
Reuter, A. M., Kennes, F., Gevaert, Y. & Franchimont, P. (1975). Homogous radioimmunoassay for human prolactin. International Journal of Nuclear Medicine and Biology 3, 21–28.CrossRefGoogle Scholar
Sourkes, T. L. (1975). Neural and neuroendocrine functions of dopamine. Psychoneuroendocrinology 1, 69–78.CrossRefGoogle Scholar
Wiles, D. H., Kolakowska, T., McNeilly, A. S., Mandelbrote, B. M. & Gelder, M. G. (1976). Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. Psychological Medicine 6, 407–415.CrossRefGoogle ScholarPubMed